The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
暂无分享,去创建一个
H. Krum | Y. Lacourciére | R. Viskoper | M. Budde | V. Charlon | Henry Krum | Reuven Viskoper | Yves Lacourcière | Michael Budde | Vincent Charlon
[1] G. Hopfgartner,et al. Pharmacokinetics and pharmacodynamics of the endothelin‐receptor antagonist bosentan in healthy human subjects , 1996, Clinical pharmacology and therapeutics.
[2] B. Psaty,et al. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.
[3] B. Löffler,et al. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). , 1994, Circulation.
[4] W. Neidhart,et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. , 1994, The Journal of pharmacology and experimental therapeutics.
[5] B. Löffler,et al. Radioimmunological Determination of Endothelin Peptides in Human Plasma: A Methodological Approach , 1994 .
[6] W. Neidhart,et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist , 1993, Nature.
[7] D. Webb,et al. The endothelin family of peptides: local hormones with diverse roles in health and disease? , 1993, Clinical science.
[8] D. Webb,et al. Endothelium-dependent modulation of responses to endothelin-I in human veins. , 1993, Clinical science.
[9] M. Yano,et al. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. , 1993, Life sciences.
[10] M. J. Sumner,et al. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction , 1992, British journal of pharmacology.
[11] J. McMurray,et al. Plasma Endothelin in Chronic Heart Failure , 1992, Circulation.
[12] P Bauer,et al. Multiple testing in clinical trials. , 1991, Statistics in medicine.
[13] S. Nakanishi,et al. Cloning and expression of a cDNA encoding an endothelin receptor , 1990, Nature.
[14] T. Sakurai,et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor , 1990, Nature.
[15] H. Yasuda,et al. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. , 1990, Journal of molecular and cellular cardiology.
[16] T. Horio,et al. Plasma immunoreactive endothelin in essential hypertension. , 1990, The American journal of medicine.
[17] K. Nakao,et al. Increased plasma endothelin level in patients with essential hypertension. , 1990, The New England journal of medicine.
[18] M. Boarder,et al. Characterization of Endothelin‐1 Stimulation of Catecholamine Release from Adrenal Chromaffin Cells , 1989, Journal of cardiovascular pharmacology.
[19] M. Redfield,et al. Integrated cardiac, renal, and endocrine actions of endothelin. , 1989, The Journal of clinical investigation.
[20] S. R. Searle,et al. Linear Models For Unbalanced Data , 1988 .
[21] J. Cohn,et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.
[22] A. Kappelgaard,et al. Measurement of angiotensin II in human plasma: technical modifications and practical experience. , 1976, Clinica chimica acta; international journal of clinical chemistry.